drugset / Trial / NCT00649376
Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's fexofenadine 180 mg tablets to Aventis' Allegra® 180 mg tablets following a single, oral 180 mg (1 x 180 mg) dose administered under fasting conditions.
Timeline
- Start
- 2003-10
- Primary completion
- 2003-11
- Completion
- 2003-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fexofenadine | Unknown | 180 mg | Oral |
Indications
No indication recorded.